Clinical Trial

Short Term Choline and Cardiovascular Health

Study Description

Short Term Choline and Cardiovascular Health

Trimethylamine-N-oxide (TMAO), a metabolite produced by gut microbial metabolism of dietary choline, has recently been causally linked to atherosclerosis in animal models and has been shown to be predictive of cardiovascular disease (CVD) risk in some but not all cohort studies. The relevance of observations in animals to humans is unclear and little information is available on the mechanisms linking TMAO to increased CVD risk. Vascular dysfunction plays a critical role in the initiation and progression of atherothrombotic disease. Whether TMAO impairs vascular function in humans is not known. The purpose of this study is to determine if short term supplementation of dietary choline, which increase TMAO, impairs vascular function.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Dietary Supplement - Choline

Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 14 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.

Dietary Supplement - Placebo

Participants will consume 1000 mg (2x500 mg) of placebo for 14 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.

Additional Information

Official Study Title

Short Term Choline Supplementation and Cardiovascular Health in Adults

Clinical Trial ID

NCT03327805

ParticipAid ID

ZdPxld